Terumo Corporation (TRUMY)
| Market Cap | 23.91B -12.5% |
| Revenue (ttm) | 7.28B +14.0% |
| Net Income | 1.01B +31.7% |
| EPS | 0.69 +31.9% |
| Shares Out | n/a |
| PE Ratio | 23.62 |
| Forward PE | n/a |
| Dividend | 0.09 (0.58%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 300 |
| Open | 16.28 |
| Previous Close | 16.22 |
| Day's Range | 16.28 - 16.31 |
| 52-Week Range | 12.08 - 19.60 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About Terumo
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents... [Read more]
Financial Performance
In fiscal year 2026, Terumo's revenue was 1.13 trillion, an increase of 9.24% compared to the previous year's 1.04 trillion. Earnings were 135.91 billion, an increase of 16.19%.
Financial numbers in JPY Financial StatementsNews
Terumo Earnings Call Transcript: Q1 2027
Record-high quarterly revenue and profit driven by strong global demand, U.S. tariff refund, and one-time settlement income. Full-year profit guidance was raised, with all major business segments contributing to growth.
Terumo Quarterly report: Q1 2027
Terumo has published its Q1 2027 quarterly earnings report on August 7, 2026.
Terumo Slides: Q1 2027
Terumo has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 7, 2026.
Terumo Transcript: Investor Day 2026
Africa and organ transplantation are key growth drivers, supported by localized infrastructure, government engagement, and innovative technologies. Next-generation devices, flexible CDMO operations, and a strong pipeline underpin robust financial guidance, with the GS31 plan to be unveiled in December.
Terumo Slides: FY 2026
Terumo has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
Terumo Earnings Call Transcript: Q4 2026
Record revenue and profit achieved for FY 2025, with strong growth across all segments and regions. FY 2026 guidance targets further record highs, driven by organic growth, new product launches, and the integration of OrganOx, despite ongoing tariff and raw material cost pressures.
Terumo Quarterly report: Q4 2026
Terumo has published its Q4 2026 quarterly earnings report on May 15, 2026.
Terumo Slides: Q4 2026
Terumo has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Terumo Earnings Call Transcript: Q3 2026
Record-high revenue and profits were achieved, driven by strong North American demand and effective pricing strategies that offset tariffs and FX headwinds. Acquisitions of Leverkusen Plant and OrganOx contributed to results, and the company remains on track to meet GS 2026 targets.
Terumo Quarterly report: Q3 2026
Terumo has published its Q3 2026 quarterly earnings report on February 13, 2026.
Terumo Slides: Q3 2026
Terumo has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 13, 2026.
Terumo Transcript: 44th Annual J.P. Morgan Healthcare Conference
Global sales growth is driven by innovation in vascular access, CDMO, and blood technologies, with a focus on margin expansion and strategic M&A. OrganOx acquisition is expected to deliver high double-digit growth and significant market impact, while U.S., Japan, China, and India remain key markets.
Terumo Slides: 44th Annual J.P. Morgan Healthcare Conference
Terumo has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
Terumo Earnings Call Transcript: Q2 2026
Record first-half revenue and profits were achieved, driven by strong North American demand, pricing measures, and cost control. Full-year guidance was revised upward, with strategic investments and the Organox acquisition expected to fuel further growth.
Terumo Quarterly report: Q2 2026
Terumo has published its Q2 2026 quarterly earnings report on November 12, 2025.
Terumo Slides: Q2 2026
Terumo has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 12, 2025.
OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation
OXFORD, England and MADISON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd.
Terumo Transcript: M&A Announcement
The acquisition of OrganOx for $1.5 billion enables entry into the high-growth organ transplantation market, leveraging innovative NMP technology to address unmet needs and expand into new domains. Synergies, cost advantages, and a strong strategic fit are expected to drive long-term growth.
Terumo Press release: M&A Announcement
Terumo issued a press release on August 27, 2025, disclosing material business information to investors.
Terumo Slides: M&A Announcement
Terumo has posted slides in relation to its latest quarterly earnings report, which was published on August 27, 2025.
IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium
Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense IceCure joined its exclusive regional distributor, Terumo...
FDA grants emergency authorization to two blood purification systems
The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.